PSA increase predicts prostate cancer outcome

The time it takes for prostate-specific antigen (PSA) levels to double can help predict the clinical outcome of patients with Prostate cancer who have been treated with combined radiation and hormone therapy, researchers report in the International Journal of Radiation Oncology, Biology, Physics.

“Since patients with PSA recurrences after treatment for Prostate cancer have significant variability in subsequent clinical outcomes, other parameters such as PSA kinetics have been used to better predict those patients who may develop symptomatic recurrences or decreased survival,” said lead investigator Dr. Andrew K. Lee.

“Brief PSA doubling time,” he continued, “has been shown to be significant for predicting clinically apparent recurrences.”

In the current study, Lee and colleagues at the University of Texas M. D. Anderson Cancer Center, Houston reviewed data on 621 men with Prostate cancer that had not spread to other areas of the body. Overall, 62 men experienced some degree of clinical failure and 22 had true clinical failure.

Only hormone therapy duration and a doubling time of 8 months or less were significantly associated with time to true clinical failure.

The estimated 5-year rate of any clinical failure was 9.4 percent for men with a doubling time of more than 8 months and 60.4 percent for those with a shorter doubling time. Corresponding values for true clinical failure were 6.5 percent and 68.5 percent. For estimated 6-year overall survival after PSA failure, the proportions were 79.1 percent and 29.7 percent.

These results, Lee concluded, “further define the role of using PSA doubling time in predicting which men may have worse clinical outcomes, including decreased survival, after combination treatment with radiation and hormonal therapy, and aid in the selection of patients for more rigorous monitoring and more aggressive...therapies.”

SOURCE: International Journal of Radiation, Biology, Physics, October 1, 2005.

RELATED STORIES:
Herbal extract may treat prostate cancer   Should older men be screened for prostate cancer?   What is the role of focal therapy in low-risk prostate cancer?   Low-grade prostate cancer may not require aggressive treatment   Beehive extract shows potential as prostate cancer treatment   Study links acetaminophen to lower prostate cancer risk   Prostate cancer surgery more costly for obese men   Predicting the Return of Prostate Cancer: New Study Betters the Odds of Success   Serum lipid levels and I-PSS or Qol are not linked in prostatic hyperplasia   Long-Term Survival Probability in Men with Clinically Localized Prostate Cancer   Aspirin, Other NSAIDs, May Prevent or Delay Enlarged Prostate   Few differences in outcomes between open and laparoscopic prostate surgery   Prostate Cancer - Patterns of Progression   Exercise helps sex life after prostate radiation   Prostate cancer cost varies widely by treatment   New gene test for prostate cancer at hand   Surgical Prospectives in High-Risk Prostate Cancer   Gleevec strangles drug-resistant, metastatic prostate cancer   New Finding Suggests Prostate Biopsy is Not Always Necessary   Urine test improves prostate diagnosis   Painkillers may cut prostate cancer risk a little   Racial disparity seen in prostate cancer treatment

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]